NEFL and Alzheimer disease: While CSF levels of beta amyloid (Aβ) and tau isoforms, together with markers of neuronal loss, such as neurofilament light (Nfl), are increasingly used as biomarkers in Alzheimer’s disease, neuroinflammatory markers are beginning to be evaluated to allow for the stratification of subjects according to the underlying molecular and cellular mechanisms leading to their impairments.